Figure 2From: PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibodyPathological analysis of immune infiltration after 4-1BB mAb therapy. Tumor CD3+, F4/80+ and CD45+ infiltrating cells were identified by immunohistochemical and immunoflurecence analysis on day 14 (a) and day 22 (b) after tumor injection. Data is also represented by pixel area of positively stained cells per 100 pixel area of viable tumor. Error bars represent mean ± SEM, *p < 0.05.Back to article page